Journal
ONCOTARGETS AND THERAPY
Volume 14, Issue -, Pages 3537-3544Publisher
DOVE MEDICAL PRESS LTD
DOI: 10.2147/OTT.S311661
Keywords
pancreatic cancer; pembrolizumab; complete response; PD-L1; locally advanced; immune checkpoint inhibitor
Categories
Ask authors/readers for more resources
PDAC, a deadly cancer type, is generally resistant to immune therapies despite advances in systemic therapies. Preoperative radiation and immunotherapy may improve treatment outcomes for PDAC patients, but more data is needed for further support.
Pancreatic ductal adenocarcinoma (PDAC) remains deadly despite advances in systemic therapies and surgical techniques. While there is increasing utilization of immune therapies across diverse cancer types, PDAC remains generally resistant to these treatments. We report a case of locally advanced PDAC treated with preoperative radiation and anti-PD-1 immunotherapy guided by preoperative PD-L1 tumor analysis. After 4 months of preoperative therapy, the patient was submitted to resection, demonstrating a near-complete pathologic response on final tumor analysis. We will discuss the relevant literature and current state of immunotherapeutics for PDAC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available